Want to see ADXN full AI Analyst Report?
ADXN Stock Chart & Stats
$3.85
-$0.25(-4.33%)
At close: 4:00 PM EDT
$3.85
-$0.25(-4.33%)
Day’s Range― - ―
52-Week Range$3.40 - $12.05
Previous CloseN/A
Volume18.00
Average Volume (3M)273.35K
Market Cap
$3.96M
Enterprise Value$5.18
Total Cash (Recent Filing)$937.50K
Total Debt (Recent Filing)$102.27K
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.97
Shares Outstanding1,822,121
10 Day Avg. Volume794,048
30 Day Avg. Volume273,353
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.20
Price to Sales (P/S)191.02
P/FCF Ratio-2.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.98
Revenue Forecast (FY)$1.79M
Bulls Say, Bears Say
Bulls Say
Strong Preclinical GABAB Cough ProgramRobust efficacy across multiple species, sustained activity, and a wide preclinical safety margin support a differentiated therapeutic profile. If confirmed clinically, this program could expand Addex’s partnering potential and create a durable pipeline asset.
Partnered Program Offers Milestone And Royalty PotentialA partner has advanced the selected compound through IND-enabling work, reducing Addex’s development burden while preserving economic upside. Milestones and royalties could provide non-dilutive value and future revenue if development and commercialization succeed.
Neurosterix Broadens Pipeline ExposureThe spinout gives Addex exposure to multiple CNS programs while externalizing much of their development activity. NTX-53’s clinical progress and additional pipeline programs could increase the strategic value of the retained equity interest over time.
Bears Say
Persistent Cash Burn And External Financing DependenceThe company is not self-funding and must secure financing or partnerships to advance important unpartnered assets. Continued cash burn raises dilution, execution, and development-delay risks, limiting strategic flexibility over the next several quarters.
Persistent Operating Losses And Declining Revenue BaseAddex lacks recurring commercial product revenue and remains dependent on collaboration economics and capital access. Ongoing operating losses make future milestone timing uncertain and increase the likelihood that equity or asset monetization will fund operations.
Tight Short-term LiquidityVery limited current assets relative to near-term liabilities indicate a constrained working-capital position. Although management expects runway into Q4 2026 on a going-concern basis, the narrow liquidity buffer leaves little room for delays or unexpected costs.
Addex Therapeutics News
ADXN FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was $3.40 and its highest was $12.05 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is $3.96M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Nov 09, 2026 which is in 64 days.
How were Addex Therapeutics’s earnings last quarter?
Addex Therapeutics released its earnings results on Jun 25, 2026. The company reported -$0.01 earnings per share for the quarter.
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Overvalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 1,822,121 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Addex Therapeutics reported an EPS of -$0.01 in its last earnings report. Following the earnings report the stock price went down -18.016%.
Which hedge fund is a major shareholder of Addex Therapeutics?
Currently, no hedge funds are holding shares in ADXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
ADXN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents meaningful scientific and preclinical progress — notably strong antitussive data for the GABAB PAM (Compound A), clear rationale and readiness for dipraglurant in post-stroke/TBI recovery, a value-creating Neurosterix spinout nearing Phase 1 readout, and a partnered program with material milestone upside via Indivior. However, these operational and pipeline positives are tempered by a constrained cash position, increasing reported losses driven by the equity-method share of Neurosterix, and the explicit need for additional financing or partnering to start IND-enabling studies and advance unpartnered programs. Overall, the company shows strong R&D momentum but meaningful near-term financing risk.View all ADXN earnings summariesTechnical Analysis
Kiora Pharmaceuticals
―
Xenetic Biosciences
―
Nucana
―
Creative Medical Technology Holdings
―
HCW Biologics
―
Ownership Overview
67.23% Insiders
0.05% Other Institutional Investors
32.71% Public Companies and
Individual Investors